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Untangling the dynamics between HIV and CD4 cellular populations and molecular interactions can be used to investigate the
effective points of interventions in theHIV life cycle.With that inmind,we propose and show the usefulness of a stochastic approach
towards modeling HIV and CD4 cells’ dynamics in vivo by obtaining probability generating function, the moment structures of
the healthy CD4 cell and the virus particles at any time t, and the probability of HIV clearance. The unique feature is that both
therapy and the intracellular delay are incorporated into the model. Our analysis shows that, when it is assumed that the drug is not
completely effective as is the case of HIV in vivo, the probability of HIV clearance depends on two factors: the combination of drug
efficacy and length of the intracellular delay and also the education of the infected patients. Comparing simulated data before and
after treatment indicates the importance of combined therapeutic intervention and intracellular delay in having low, undetectable
viral load in HIV-infected person.
1. Introduction
Since HIV pandemic first became visible, enormous math-
ematical models have been developed to describe the
immunological response to infection with human immun-
odeficiency virus (HIV). Mathematical modeling has proven
to be valuable in understanding the dynamics of infectious
diseases with respect to host-pathogen interactions. When
HIV enters the body, it targets all the cells with CD4 receptors
including the CD4 T cells. The knowledge of principal
mechanisms of viral pathogenesis, namely, the binding of the
retrovirus to the gp120 protein on the CD4 cell, the entry of
the viral RNA into the target cell, the reverse transaction of
viral RNA to viral DNA, the integration of the viral DNAwith
that of the host, and the action of viral protease in cleaving
viral proteins into mature products, has led to the design of
drugs (chemotherapeutic agents) to control the production of
HIV.
Chronic HIV-infection causes gradual depletion of the
CD4 T-cell poll and, thus, progressively compromises the
host’s immune response to opportunistic infections, leading
to acquired immunodeficiency syndrome (AIDS) [1]. With
the spread of the HIV-AIDS pandemic and in the absence
of an “effective” vaccine or cure, therapeutic interventions
are still heavily relied on. Several research studies have
been carried out in the recent past, both theoretically and
experimentally, to analyse the impact of therapy on the
viral load in HIV-infected persons in order to ascertain
the effectiveness of the treatment (see, e.g., [2–8]). Their
utility lies in the ability to predict an infected steady state
and examining the effects that the changes in parameters
have on the outcome of the system over time to determine
which parameters are most important in disease progression,
and further determine critical threshold values for these
parameters.
In HIV-infected individuals, the infection exhibits a long
asymptomatic phase (after the initial high infectious phase)
of approximately 10 years on average before the onset of
AIDS. During this incubation period, which some call the
clinical latency period, the individuals appear to be well and
may contribute significantly to the spread of the epidemic
in a community [9]. Some clinical markers such as the
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CD4 cell count and the RNA viral load (viraemia) provide
information about the progression of the disease in infected
individuals. Also, the clinical latency period of the disease
may provide a sufficiently long period during which one
can attempt an effective suppressive therapeutic intervention
in HIV infections. Various biological reasons lead to the
introduction of time delays inmodels of disease transmission.
Time delays are used to model the mechanisms in the disease
dynamics (see, e.g., [10, 11]).
Intracellular delays and the target-cell dynamics such as
mitosis are two key factors that play an important role in
the viral dynamics. Mitosis in healthy or infected target-
cell population are typically modelled by a logistic term
[2, 12–16]. Intracellular delays have been incorporated into
the incidence term in finite or distributed form [4, 17–
23]. In [13, 16], in-host viral models with a logistic growth
term without intracellular delays are investigated, and it is
shown that sustained oscillations can occur through Hopf
bifurcation when the intrinsic growth rate increases. It is
shown in [17, 23], in in-host models with both a logistic
growth term and intracellular delay, that Hopf bifurcations
can occurwhen the intracellular delay increases. In [19], using
in-host models with a general form of target-cell dynamics
and general distributions for intracellular delays, it is shown
that the occurrence of Hopf bifurcation in these models
critically depends on the form of target-cell dynamics. More
specifically, it is proved in [20] that, if the target-cell dynamics
are such that no Hopf bifurcations occur when delays are
absent, introducing intracellular delays in the model will not
lead to Hopf bifurcations or periodic oscillations.
To incorporate the intracellular delay phase of the virus
life cycle, [24] assumed that virus production occurs after
the virus entry by a constant delay 𝜏. They came up with
a basic in-host compartmental model of the viral dynamics
containing three compartments: 𝑥(𝑡), 𝑦(𝑡), and V(𝑡) denoting
the populations of uninfected target cells, infected target cells
that produce virus, and free virus particles, respectively.They
further assumed that parameters 𝛿,𝛼, and𝜇 are turnover rates
of the 𝑥, 𝑦, and V compartments, respectively. Uninfected
target cells are assumed to be produced at a constant rate
𝜆. They assumed also that cells infected at time 𝑡 will be
activated and produce viral materials at time 𝑡 + 𝜏. In their
model, constant 𝑠 is the death rate of infected but not yet
virus-producing cells, and 𝑒−𝑠𝜏 describes the probability of
infected target cells surviving the period of intracellular delay
from 𝑡 − 𝜏 to 𝑡. Constant 𝜅 denotes the average number of
virus particles that each infected cell produces. Preceding




= 𝜆 − 𝛿𝑥 (𝑡) − 𝛽𝑥 (𝑡) V (𝑡) ,
𝑑𝑦
𝑑𝑡
= 𝛽𝑥 (𝑡 − 𝜏) V (𝑡 − 𝜏) 𝑒
−𝑠𝜏
− 𝛼𝑦 (𝑡) ,
𝑑V
𝑑𝑡
= 𝜅𝑦 (𝑡) − 𝜇V (𝑡) .
(1)
System (1) can be used tomodel the infection dynamics of
HIV, HBV, and other viruses [2, 12–14, 25, 26]. It can also be
considered as a model for the HTLV-I infection if 𝑥(𝑡), 𝑦(𝑡),
and V(𝑡) are regarded as healthy, latently infected, and actively
infected CD4 T cells [14, 15]. For detailed description and
derivation of the model, as well as the incorporation of
intracellular delays, we refer the reader to [24].
From the literature, many researchers have employed
deterministic models to study HIV internal dynamics, ignor-
ing the stochastic effects. We consider a stochastic model
for the interaction of HIV virus and the immune system
in an HIV-infected individual undergoing a combination-
therapeutic treatment. Our aim in this paper is to use
a stochastic model obtained by extending the model of
[24] to determine the probability distribution, variance and
covariance structures of the uninfected CD4+ cells, infected
CD4 cells, and the freeHIV particles in an infected individual
at any time 𝑡 by examining the combined antiviral treatment
of HIV. Based on the model, we obtain joint probability
distribution, expectations, variance and covariance structures
of variables representing the numbers of uninfected CD4
cells, theHIV-infectedCD4T cells, and the freeHIVparticles
at any time 𝑡 and derive conclusions for the reduction or
elimination of HIV in HIV-infected individuals, which is one
of the main contributions of this paper.
The organization of this paper is as follows: in Section 2,
we formulate our stochastic model describing the interac-
tion of HIV and the immune system and obtain a partial
differential equation for the probability generating function
of the numbers of uninfected CD4 cells, the HIV-infected
CD4 T cells, and the free HIV particles at any time 𝑡, also
moments for the variables are derived here. In Section 3,
we derive the moments of the variables in a therapeutic
environment and probability of extinction of HIV virus and
also provide a numerical illustration to demonstrate the
impact of intercellular delay and therapeutic intervention in
controlling the progression ofHIV. Some concluding remarks
follow in Section 4.
2. HIV and CD4 Cells Dynamics before
Therapeutic Intervention
To study the interaction of HIV virus and the immune
system, we propose a stochastic model by extending the
deterministic model presented in the literature. A stochastic
process is defined by the probabilities with which different
events happen in a small time intervalΔ𝑡. In ourmodel, there
are two possible events (production and death/removal) for
each population (uninfected cells, infected cells, and the free
virons). The corresponding rates in the deterministic model
are replaced in the stochastic version by the probabilities that
any of these events occur in a small time interval Δ𝑡.
(1) The Interaction of HIV Virus and the CD4 T-Cells. A
typical life-cycle ofHIVvirus and immune system interaction
is shown in Figure 1.
Let 𝑋(𝑡) be the size of the healthy cells population at
time 𝑡, 𝑌(𝑡) be the size of infected cell population at time
𝑡, and 𝑉(𝑡) be the size of the virons population at time
































Figure 1: The interaction of HIV virus and the CD4+ T cells.
instead of rates of births and deaths, there is a possibility
of stochastic births or deaths of the heathy cells, infected
cells and the virus particles. Thus, 𝑋(𝑡), 𝑌(𝑡), and 𝑉(𝑡) are
time-dependent randomvariables.This epidemic process can
be modeled stochastically by letting the nonnegative integer
values process 𝑋(𝑡), 𝑌(𝑡), and 𝑉(𝑡), respectively, represent
the number of healthy cells, infected cells, and virons of the
disease at time 𝑡. Then, {(𝑋(𝑡), 𝑌(𝑡), 𝑉(𝑡)) : 𝑡 ≥ 0} can be
modeled as continuous time multivariate Markov chain. Let
the probability of there being 𝑥 healthy cells, 𝑦 infected cells,
and V virons in an infected person at time 𝑡 be denoted by
the following joint probability function: 𝑃
𝑥,𝑦,V(𝑡) = 𝑃[𝑋(𝑡) =
𝑥, 𝑌(𝑡) = 𝑦, 𝑉(𝑡) = V], for 𝑥, 𝑦, V = 0, 1, 2, 3 . . ..
The standard argument using the forward Chapman-
Kolmogorov differential equations is used to obtain the
joint probability function 𝑃
𝑥,𝑦,V(𝑡), by considering the joint
probability 𝑃
𝑥,𝑦,V(𝑡, 𝑡 + Δ𝑡). This joint probability is obtained
as the sum of the probabilities of the following mutually
exclusive events.
(2) Population Change Scenarios. Consider the following
points.
(1) There were 𝑥 healthy cells, 𝑦 infected cells, and V
virons by time 𝑡, and nothing happens during the time
interval (𝑡, 𝑡 + Δ𝑡).
(2) There were 𝑥 − 1 healthy cells, 𝑦 infected cells, and
V virons by time 𝑡, and one healthy cell is produced
from the thymus during the time interval (𝑡, 𝑡 + Δ𝑡).
(3) There were 𝑥 + 1 healthy cells, 𝑦 infected cells, and V
virons by time 𝑡, and one healthy cell dies or is infected
by HIV virus during the time interval (𝑡, 𝑡 + Δ𝑡).
(4) There were 𝑥 healthy cells, 𝑦 − 1 infected cells, and
V virons by time 𝑡, and one healthy cell is infected by
HIV virus during the time interval (𝑡, 𝑡 + Δ𝑡).
(5) There were 𝑥 healthy cells, 𝑦 + 1 infected cells, and
V virons by time 𝑡 and one infected cell dies (HIV-
infected cell bursts or undergoes a lysis) during the
time interval (𝑡, 𝜏).
(6) There were 𝑥 healthy cells, 𝑦 infected cells, and
V − 1 virons by time 𝑡 and one viron is produced
(HIV-infected cell undergoes a lysis or the individual
angages in risky behaviour) during the time interval
(𝑡, 𝑡 + Δ𝑡).
(7) There were 𝑥 healthy cells, 𝑦 infected cells, and V + 1
virons by time 𝑡, and one viron dies during the time
interval (𝑡, 𝑡 + Δ𝑡).
We incorporate a time delay between infection of a cell
and production of new virus particles, we let 𝜏 be the time lag
between the time the virus contacts a target CD4 T cell and
the time the cell becomes productively infected (including
the steps of successful attachment of the virus to the cell and
penetration of virus into the cell); this means the recruitment
of virus producing cells at time 𝑡 is given by the density of cells
that were newly infected at time 𝑡−𝜏 and are still alive at time
𝑡. If we also let 𝜌 be the death rate of infected but not yet virus
producing cell, then the probability that the infected cell will
survive to virus producing cell during the short time interval
𝜏 will be given by 𝑒−𝜌𝜏.
(3) Variables and Parameters for the Model. The variables and
parameters in the model are described as in Table 1.
Using the population change scenarios and parameters
in Table 1, we now summarize the events that occur during
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Table 1: (a) Variables for the stochastic model. (b) Parameters for
the stochastic model.
(a)
Variable Description Initial condition
𝑡 = 0
𝑋(𝑡)
The concentration of uninfected
CD4 cells at time 𝑡 100
𝑌(𝑡)
The concentration of infected CD4
cells at time 𝑡 0.02
𝑉(𝑡)
The concentration of virus particles
at time 𝑡 0.001
(b)
Parameter
symbol Parameter description Estimate
(1 − 𝛼)
The reverse transcriptase inhibitor
drug effect 0.5
(1 − 𝜔) The protease inhibitor drug effect 0.5
𝜆
The total rate of production of healthy
CD4 cells 10
𝛿
The per capita death rate of healthy
CD4 cells 0.02
𝛽
The transmission coefficient between




Per capita death rate of infected CD4
cells 0.5
𝛾
The virus production rate due to risk
behaviors 0.001
𝜇
The per capita death rate of infective
virus particles 3
𝜌
The death rate of infected but not yet
virus producing cell 0.5
𝜏 Time lag during infection 0.5
𝑁
The average number of infective virus
particles produced by an infected
CD4 cell in the absence of treatment
during its entire infectious lifetime
1000
the interval (𝑡, 𝑡 + Δ) together with their transition probabili-
ties in Table 2.
The change in population size during the time intervalΔ𝑡,
which is assumed to be sufficiently small to guarantee that
only one such event can occur in (𝑡, 𝑡 + Δ𝑡), is governed by
the following conditional probabilities:
𝑃
𝑥,𝑦,V (𝑡 + Δ𝑡)
= {1 − (𝜆Δ𝑡 + 𝛿𝑥Δ𝑡 + 𝛽𝑥VΔ𝑡 + 𝜇VΔ𝑡 + 𝜅𝑦Δ𝑡 + 𝛾Δ𝑡)
+ 𝑜 (Δ𝑡)} 𝑃
𝑥,𝑦,V (𝑡)
+ {𝜆Δ𝑡 + 𝑜 (Δ𝑡)} 𝑃
𝑥−1,𝑦,V (𝑡)
+ {𝛿 (𝑥 + 1) Δ𝑡 + 𝑜 (Δ𝑡)} 𝑃
𝑥+1,𝑦,V (𝑡)
+ {𝛽 (𝑥 + 1) (V + 1) 𝑒
−𝜌𝜏
Δ𝑡 + 𝑜 (Δ𝑡)}
× 𝑃
𝑥+1,𝑦−1,V+1 (𝑡)
+ {𝜅𝑁 (𝑦 + 1) Δ𝑡 + 𝑜 (Δ𝑡)} 𝑃
𝑥,𝑦+1,V−1 (𝑡)
+ {𝛾Δ𝑡 + 𝑜 (Δ𝑡)} 𝑃
𝑥,𝑦,V−1 (𝑡)
+ {𝜇 (V + 1) Δ𝑡 + 𝑜 (Δ𝑡)} 𝑃
𝑥,𝑦,V+1 (𝑡) .
(2)
Simplifying (2), we have the following forward Kolmogorov




𝑥,𝑦,V (𝑡) = − {𝜆 + 𝛿𝑥 + 𝛽𝑒
−𝜌𝜏
𝑥V + 𝜇V + 𝜅𝑁𝑦 + 𝛾} 𝑃
𝑥,𝑦,V (𝑡)
+ 𝜆𝑃
𝑥−1,𝑦,V (𝑡) + 𝛿 (𝑥 + 1) 𝑃𝑥+1,𝑦,V (𝑡)




+ 𝑁𝜅 (𝑦 + 1) 𝑃
𝑥,𝑦+1,V−1 (𝑡) + 𝛾𝑃𝑥,𝑦,V−1 (𝑡)
+ 𝜇 (V + 1) 𝑃
𝑥,𝑦,V+1 (𝑡) .
(3)
This will also be referred to as the Master equation or the











2.1. The Probability Generating Function. The probability



































































































































and summing over 𝑥,𝑦, and V, then





− 1) 𝜆 + (𝑧
3
− 1) 𝛾}𝐺







































Table 2: Transitions of in-host interaction of HIV.
Possible transitions in host interaction of HIV and immune system cells and corresponding probabilities
Event Population(𝑋,𝑌, 𝑉) at 𝑡
Population
(𝑋,𝑌, 𝑉) at (𝑡, 𝑡 + Δ)
Probability
of transition
Production of uninfected cell (𝑥 − 1, 𝑦, V) (𝑥, 𝑦, V) 𝜆Δ𝑡
Death of uninfected cell (𝑥 + 1, 𝑦, V) (𝑥, 𝑦, V) 𝛿(𝑥 + 1)Δ𝑡
Infection of uninfected cell (𝑥 + 1, 𝑦 − 1, V + 1) (𝑥, 𝑦, V) 𝛽(𝑥 + 1)(V + 1)𝑒−𝜌𝜏Δ𝑡
Production of virons from the bursting infected cell (𝑥, 𝑦 + 1, V − 1) (𝑥, 𝑦, V) 𝜅𝑁(𝑦 + 1)Δ𝑡
Introduction of virons due to reinfection because of risky behaviour (𝑥, 𝑦, V − 1) (𝑥, 𝑦, V) 𝛾Δ𝑡
Death of virons (𝑥, 𝑦, V + 1) (𝑥, 𝑦, V) 𝜇(V + 1)Δ𝑡
This is called Lagrange partial differential equation for the
probability generating function (pgf).
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where 𝑎 and 𝑏 are constants.







). However, it is possible to obtain the moment
structure of (𝑋(𝑡); 𝑌(𝑡); 𝑉(𝑡)) from (8).
2.2. The Marginal Generating Functions. Recall that
𝐺 (𝑧
1




























1 and solving (8), we obtain the marginal partial generating


































































































































= 𝐸 [𝑋] . (13)
Differentiating the partial differential equations of the pgf, we
get the moments of𝑋(𝑡), 𝑌(𝑡), and 𝑉(𝑡).
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= 1, we have
𝜕
𝜕𝑡
𝐸 [𝑋 (𝑡)] = 𝜆 − 𝛿𝐸 [𝑋 (𝑡)] − 𝛽𝐸 [𝑋 (𝑡) 𝑉 (𝑡)] ,
𝜕
𝜕𝑡
𝐸 [𝑌 (𝑡)] = −𝜅𝐸 [𝑌 (𝑡)] + 𝛽𝑒
−𝜌𝜏




= 𝛾 + 𝑁𝜅𝐸 [𝑌 (𝑡)] − 𝜇𝐸 [𝑉 (𝑡)] − 𝛽𝐸 [𝑋 (𝑡) 𝑉 (𝑡)] .
(14)
Therefore, the moments of (𝑋(𝑡), 𝑌(𝑡), 𝑉(𝑡)) from the pgf
before treatment are as follows:
𝜕
𝜕𝑡
𝐸 [𝑋 (𝑡)] = 𝜆 − 𝛿𝐸 [𝑋 (𝑡)] − 𝛽𝐸 [𝑋 (𝑡) 𝑉 (𝑡)] ,
𝜕
𝜕𝑡
𝐸 [𝑌 (𝑡)] = −𝜅𝐸 [𝑌 (𝑡)] + 𝛽𝑒
−𝜌𝜏




= 𝛾 + 𝑁𝜅𝐸 [𝑌 (𝑡)] − 𝜇𝐸 [𝑉 (𝑡)] − 𝛽𝐸 [𝑋 (𝑡) 𝑉 (𝑡)] .
(15)
The corresponding deterministic model of HIV-host interac-
tion as formulated in [24] is given as follows:
𝑑𝑥
𝑑𝑡





𝑥 (𝑡 − 𝜏) V (𝑡 − 𝜏) − 𝜅𝑦 (𝑡) ,
𝑑V
𝑑𝑡
= 𝛾 + 𝑁𝜅𝑦 (𝑡) − 𝜇V (𝑡) − 𝛽𝑥 (𝑡) V (𝑡) .
(16)
Comparing system of (15) with the system of (16), we see
that expected values of the multivariate Markov process
[𝑋(𝑡), 𝑌(𝑡), 𝑉(𝑡)] satisfies the corresponding deterministic
model of the HIV-host interaction dynamics.
2.3.1. Simulation. Using the parameter values and initial con-
ditions defined in Table 1, we illustrate the general dynamics
of the CD4-T cells and HIV virus for model (15) during
infection and in the absence of treatment.
The second graph in Figure 2 is the population dynamics
after taking the logarithm of the cell populations in the first
graph.
From the simulations, it is clear that in the primary
stage of the infection (period before treatment), a dramatic
decrease in the level of the CD4-T cells occurs and the
number of the free virons increases with time. With the
introduction of intracellular delay, the virus population drops
as well as an increase in the CD4, cells but then they stabilize
at some point and coexist in the host as shown in Figure 2.
3. HIV and CD4 Cells Dynamics under
Therapeutic Intervention
Assume that at time 𝑡 = 0, a combination therapy treatment
is initiated in an HIV-infected individual. We assume that
the therapeutic intervention inhibits either the enzyme action
of reverse transcriptase or that of the protease of HIV in an
HIV-infected cell. An HIV-infected cell with the inhibited
HIV-transcriptase may be considered a dead cell as it cannot
participate in the production of the copies of any type of
HIV. On the other hand, an HIV-infected cell in which
the reverse transcription has already taken place and the
viral DNA is fused with the DNA of the host, but the
enzyme activity of HIV-protease is inhibited, undergoes a
lysis releasing infectious free HIV and noninfectious free
HIV. A noninfectious free HIV cannot successfully infect
a CD4 cell. Accordingly, at any time 𝑡, the blood of the
infected person contains virus producing HIV-infected cells,
infectious free HIV, and noninfectious free HIV. A typical
life cycle of HIV virus and immune system interaction with
therapeutic intervention is shown in Figure 3.
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3.1. The Marginal Generating Functions. Recall that
𝐺 (𝑧
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= 1 and solving
(17), we obtain the marginal partial generating functions for
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Figure 2: The figure shows the CD4 cells and HIV virus population dynamics before therapeutic intervention and when 𝜏 = 0, 1.5, and 2






































3.2. Numbers of CD4+ T Cells and Virons under Therapeutic













Letting 𝑧 = 1, we have the expected number of target CD4+
T cells𝑋(𝑡) as follows:






















Differentiating the partial differential equations of the
pgf, we get the moments of𝑋(𝑡), 𝑌(𝑡), and 𝑉(𝑡).













= 1, we have
𝜕
𝜕𝑡
𝐸 [𝑋 (𝑡)] = 𝜆 − 𝛿𝐸 [𝑋 (𝑡)] − (1 − 𝛼) 𝛽𝐸 [𝑋 (𝑡) 𝑉 (𝑡)] ,
𝜕
𝜕𝑡
𝐸 [𝑌 (𝑡)] = −𝜅𝐸 [𝑌 (𝑡)] + (1 − 𝛼) 𝛽𝑒
−(1−𝛼)𝜌𝜏
𝐸 [𝑋 (𝑡) 𝑉 (𝑡)] ,
𝜕
𝜕𝑡
𝐸 [𝑉 (𝑡)] = 𝛾 + (1 − 𝜔)𝑁𝜅𝐸 [𝑌 (𝑡)] − 𝜇𝐸 [𝑉 (𝑡)]

























Figure 3: HIV-host interaction with treatment.
Therefore, the moments of (𝑋(𝑡), 𝑌(𝑡), 𝑉(𝑡)) from the pgf
with therapeutic intervention are
𝜕
𝜕𝑡
𝐸 [𝑋 (𝑡)] = 𝜆 − 𝛿𝐸 [𝑋 (𝑡)] − (1 − 𝛼) 𝛽𝐸 [𝑋 (𝑡) 𝑉 (𝑡)] ,
𝜕
𝜕𝑡
𝐸 [𝑌 (𝑡)] = −𝜅𝐸 [𝑌 (𝑡)] + (1 − 𝛼) 𝛽𝑒
−(1−𝛼)𝜌𝜏
𝐸 [𝑋 (𝑡) 𝑉 (𝑡)] ,
𝜕
𝜕𝑡
𝐸 [𝑉 (𝑡)] = 𝛾 + (1 − 𝜔)𝑁𝜅𝐸 [𝑌 (𝑡)]
− 𝜇𝐸 [𝑉 (𝑡)] − (1 − 𝛼) 𝛽𝐸 [𝑋 (𝑡) 𝑉 (𝑡)] .
(23)
3.2.1. Simulation. Using the parameter values and initial con-
ditions defined in Table 1, we illustrate the general dynamics
of the CD4-T cells and HIV virus for model (23) with
therapeutic intervention and test the effect of intracellular
delay and drug efficacy (perform sensitivity analysis).
With 60% drug efficacy, the virus stabilizes and coexists
with the CD4 cells within the host as shown in the first graph
in Figure 4.
Introducing intracellular time delay, 𝜏 = 0.5, the CD4
cells increase and the virus population drops then stabilizes
and again coexists within the host as illustrated in the second
graph in Figure 4.
For 𝜏 = 1 and with 60% drug efficacy, the dynamics
change as shown in the last graph in Figure 4.
We now analyze drug effectiveness on the cell popula-
tions.
Figure 5 shows that, with improved HIV drug efficacy, a
patient on treatment will have low, undetectable viral load
with time. It also shows that the protease inhibitor drug
efficacy is very important in clearing the virus. Also the figure
shows that a combination of therapeutic intervention and
intracellular delay is very important in lowering the viral load
in an HIV-infected person.
3.3. The Probability of HIV Clearance. We now calculate the
distribution of times to extinction for the virons reservoir.
If we assume the drug given at fixed intervals to sustain its
efficacy to be effective in producing noninfectious virus, then
we can clear the infectious virus. Using reverse transcriptase
(ART), the infected cell can be forced to become latently
infected (nonvirus producing cell) hence clearing the virus
producing cell reservoir. If we assume that no newly infected
cells become productively infected in the short time 𝜏(𝑒−𝜌𝜏 =
0) or that treatment is completely effective (𝜔 = 1), we can
obtain the extinction probability analytically. In this case, the
infectious virus cell dynamics decouples from the rest of the
model and can be represented as a pure immigration-and-
death process with master equation
𝑃
󸀠
V (𝑡) = − (𝛾 + 𝜅 (1 − 𝜔)𝑁)𝑃V (𝑡)
− V (𝜇 + (1 − 𝛼) 𝑒
−𝜌𝜏
𝛽) 𝑃V (𝑡)
+ (V − 1) (𝛾 + 𝜅 (1 − 𝜔)𝑁)𝑃V−1 (𝑡)
+ (V + 1) (𝜇 + (1 − 𝛼) 𝑒
−𝜌𝜏
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Figure 4:The figure shows the CD4 cells and HIV virus population dynamics with drug efficacy of 60% and 𝜏 = 0, 0.5, and 1 days.The other
parameters and initial conditions are given in Tables 1 and 2.
where 𝑃V(𝑡) is the probability that, at time 𝑡, there are V
HIVparticles.This probability has the conditional probability
generating function
𝐺V (𝑧, 𝑡) |𝑉(0)=V0
= exp{𝜃
𝜖












is the initial virus reservoir size, 𝜃 = 𝜇+(1−𝛼)𝛽𝑒−𝜌𝜏
and 𝜖 = 𝛾 + (1 − 𝜔)𝜅𝑁. We noticed that this is a pgf of
a random variable with a product of Poisson distribution
exp{(𝜃/𝜖)(𝑧 − 1)(1 − 𝑒−𝜃𝑡)} with mean (𝜃/𝜖)(1 − 𝑒−𝜃𝑡) and a
binomial distribution {𝑧𝑒−𝜃𝑡 + 1 − 𝑒−𝜃𝑡}V0 .
The probability of this population going extinct at 𝑡 or
before time 𝑡 is given by











The probability of extinction is the value of𝐺V(𝑧, 𝑡)when 𝑡 →
∞, that is,




















From (27), it is evident that probability of clearance of HIV is
affected by the combination of drug efficacy and intracellular
delay, death of the virons and education (counseling the HIV
patients on the risk of involvement in risk behaviors).
4. Discussion and Recommendation
In this study, we derived and analyzed a stochastic model for
in-host HIV dynamics that included combined therapeutic
treatment and intracellular delay between the infection of a
cell and the emission of viral particles. This model included
dynamics of three compartments—the number of healthy
CD4 cells, the number of infected CD4 cells, and the HIV
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Figure 5: Shows theCD4 cells andHIV virus population dynamicswith 𝜏 = 0.5 days and different levels of drug efficacy.Theother parameters
and initial conditions are given in Tables 1 and 2.
and during therapy. We derived equations for the probability
generating a function and using numerical techniques. In this
paper we showed the usefulness of our stochastic approach
towards modeling HIV dynamics by obtaining moment
structures of the healthy CD4+ cell and the virus particles
over time 𝑡. We simulated the mean number of the healthy
CD4 cell, the infected cells, and the virus particles before and
after combined therapeutic treatment at any time 𝑡. We will
emphasize further usefulness of stochastic models in HIV
dynamics in our future research.
Our analysis during treatment shows that, when it is
assumed that the drug is not completely effective, as it is the
case of HIV in vivo, the predicted rate of decline in plasma
HIV virus concentration depends on three factors: the death
rate of the virons, the efficacy of therapy, and the length of
the intracellular delay. Our model produces an interesting
feature that the successfully treated HIV patients will have
low, undetectable viral load. We conclude that to control the
concentrations of the virus and the infected cells in HIV-
infected person, a strategy should aim to improve the cure
rate (drug efficacy) and also to increase the intracellular delay
𝜏. Therefore, the efficacy of the protease inhibitor and the
reverse transcriptase inhibitor and also the intracellular delay
play crucial role in preventing the progression of HIV.
The extinction probability model showed that the time it
takes to have low, undetectable viral load (infectious virus)
in an HIV-infected patient depends on the combination of
drug efficacy and intracellular delay and also education of the
infected patients. In our work, the dynamics of mutant virus
were not considered, and also our study included dynamics
of only three compartments (healthy CD4 cell, infected CD4
cells, and infectious HIV virus particles) of which extensions
are recommended for further extensive research. In a follow-
up work, we intend to obtain real data in order to test the
efficacy of our models as we have done here with simulated
data.
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